iSpecimen (NASDAQ:ISPC) Trading Down 4.6% – Time to Sell?

iSpecimen Inc. (NASDAQ:ISPC) shares fell 4.6% on Wednesday . The company traded as low as $2.26 and last traded at $2.29. 40,362 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 70,025 shares. The stock had previously closed at $2.40.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Tuesday, April 21st. Wall Street Zen raised iSpecimen to a “sell” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

iSpecimen Stock Down 1.6%

The company has a fifty day moving average price of $3.35 and a 200-day moving average price of $7.81. The stock has a market capitalization of $3.81 million, a P/E ratio of -0.03 and a beta of 1.63.

iSpecimen (NASDAQ:ISPC) last announced its quarterly earnings results on Friday, May 15th. The company reported ($6.66) EPS for the quarter. The firm had revenue of $0.16 million for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative return on equity of 584.65%.

Institutional Investors Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC acquired a new position in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent SEC filing. Hedge funds and other institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.